Rare cases of stroke reported with alemtuzumab

 

The U.S. Food and Drug Administration (FDA) has issued a black-box warning about a risk of stroke and arterial dissection in patients with multiple sclerosis who have been exposed to alemtuzumab (www.fda.gov/Drugs/DrugSafety/ucm624247.htm?fbclid=IwAR2eBbqp24E0J3VIk8jbUZZ5pet…).  The announcement was issued on November 29, 2018 and a black-box warning was added to the U.S. product label. The Canadian product monograph had not been updated at the time of writing.

It takes 30 seconds

TOPICS:
Recommend to a Colleague

Related Posts

Go back to home page